Sistema de Salut de Catalunya
Institut Català de la Salut
[Rojano-Toimil A] Servei d’Endocrinologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Rivera-Esteban J] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Unitat Hepàtica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Manzano-Nuñez R, Bañares J] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Unitat Hepàtica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Martinez Selva D] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Spanish Network of Biomedical Research Centers, Diabetes and Metabolic Associated Disorders (CIBERdem), Madrid, Spain. [Gabriel-Medina P] Servei de Bioquímica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Ferrer R] Servei de Bioquímica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Pericàs JM] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Unitat Hepàtica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Spanish Network of Biomedical Research Centers, Liver and Digestive Diseases (CIBERehd), Madrid, Spain. [Ciudin A] Servei d’Endocrinologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Spanish Network of Biomedical Research Centers, Diabetes and Metabolic Associated Disorders (CIBERdem), Madrid, Spain
Vall d'Hebron Barcelona Hospital Campus
2022-09-12T09:30:12Z
2022-09-12T09:30:12Z
2022-06-08
MODY diabetes; Liver fibrosis; Type 2 diabetes
Diabetes MODY; Fibrosis hepática; Diabetes tipo 2
Diabetis MODY; Fibrosi hepàtica; Diabetis tipus 2
Type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) have been traditionally linked to one another. Recent studies suggest that NAFLD may be increasingly common in other types of diabetes such as type 1 diabetes (T1DM) and less frequently ketone-prone and Maturity-onset Diabetes of the Young (MODY) diabetes. In this review, we address the relationship between hyperglycemia and insulin resistance and the onset and progression of NAFLD. In addition, despite the high rate of patients with T2DM and other diabetes phenotypes that can alter liver metabolism and consequently develop steatosis, fibrosis, and cirrhosis, NALFD screening is not still implemented in the daily care routine. Incorporating a clinical algorithm created around a simple, non-invasive, cost-effective model would identify high-risk patients. The principle behind managing these patients is to improve insulin resistance and hyperglycemia states with lifestyle changes, weight loss, and new drug therapies.
Article
Published version
English
Fenotip; Diabetis no-insulinodependent; Esteatosi hepàtica - Diagnòstic; DISEASES::Endocrine System Diseases::Diabetes Mellitus::Diabetes Mellitus, Type 2; DISEASES::Digestive System Diseases::Liver Diseases::Fatty Liver::Non-alcoholic Fatty Liver Disease; Other subheadings::Other subheadings::/diagnosis; PHENOMENA AND PROCESSES::Genetic Phenomena::Phenotype; ENFERMEDADES::enfermedades del sistema endocrino::diabetes mellitus::diabetes mellitus tipo II; ENFERMEDADES::enfermedades del sistema digestivo::enfermedades hepáticas::hígado graso::esteatosis hepática no alcohólica; Otros calificadores::Otros calificadores::/diagnóstico; FENÓMENOS Y PROCESOS::fenómenos genéticos::fenotipo
MDPI
Journal of Clinical Medicine;11(12)
https://doi.org/10.3390/jcm11123286
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - VHIR [1664]
